CNJ.TO  Cangene Cp




Life Sciences


Market Cap.


Vuru Grade


Current Price

0.00 (0.00%)

Growth Price

Undervalued by 25.65%

Stability Price

Overvalued by 39.67%

Company Metrics

  • P/E 169
  • P/S 2.08
  • P/B 1.25
  • EPS -0.15
  • Cash ROIC 5.13%
  • Cash Ratio 1.47
  • Dividend 0 / 0%
  • Avg. Vol. 255,197.00
  • Shares 66.75M
  • Market Cap. 240.3M

Company Description

Cangene Corporation develops, manufactures, and commercializes therapeutics for infectious diseases or biodefence applications in the United States, Canada, and internationally. The company develops hyperimmunes, which are concentrated specialty antibody preparations made from plasma; and recombinant biopharmaceuticals that are therapeutic proteins made by introducing a particular gene into a host... more

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


Emergent BioSolutions Completes Acquisition of Cangene Corporation
Business Wire (press release) - Feb 21, 2014
ROCKVILLE, Md.--(BUSINESS WIRE)--Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has completed its acquisition of Cangene Corporation for $222 million in cash. After payment by Cangene of transaction related costs, Emergent expects ...
Cangene Announces Completion of Acquisition by Emergent BioSolutions - Canada NewsWire (press release)
Emergent BioSolutions pays $222M to acquire life sciences firm Cangene Corp.
Washington Post - Dec 12, 2013
Emergent BioSolutions established itself as a leading biodefense company by selling Anthrax vaccines en masse to the federal government in the wake of Sept.
Cangene bought by US rival for $236-million, latest Canadian biotech taken private - The Globe and Mail
Emergent BioSolutions expanding with $222M deal to buy Cangene - FiercePharma
Ipsen and Inspiration Biopharmaceuticals Announce Closing of the IB1001 Sale ...
Business Wire (press release) - Feb 20, 2013
Ipsen (Paris:IPN) (Euronext: IPN; ADR: IPSEY) and Inspiration Biopharmaceuticals Inc. (Inspiration) today announced the closing of the sale of the proprietary hemophilia B product, IB1001 (recombinant FIX), to Cangene Corporation (TSX: CNJ) (Cangene).
Ipsen, Inspiration Biopharmaceuticals sell IB1001 hemophilia B product to Cangene -
Cangene To Be Acquired By Emergent BioSolutions For US$222 Million
Canada NewsWire (press release) - Dec 11, 2013
11, 2013 /CNW/ - Cangene Corporation ("Cangene") (TSX: CNJ) today announced the signing of a definitive agreement under which Emergent BioSolutions ("Emergent") (NYSE: EBS) of Rockville, Maryland will acquire Cangene in an all-cash transaction ...
PR Newswire (press release) - May 2, 2011
BALTIMORE AND WINNIPEG, May 2 /PRNewswire/ - Cangene Corporation's Baltimore-based injectable pharmaceutical contract-manufacturing subsidiary, Cangene bioPharma, Inc., has completed a US$11-million renovation of its sterile filling and support ...
Cangene Appoints New Chief Financial Officer
Canada NewsWire (press release) - Jun 15, 2012
WINNIPEG, June 15, 2012 /CNW/ - Cangene Corporation, a biopharmaceutical company primarily focused on hospital based therapeutics, today announces that it has appointed Mr. Jeff Lamothe as its new Chief Financial Officer, to be effective August 1, ...
Cangene Wins US FDA Approval for Antidote to Botulism
Bloomberg - Mar 22, 2013
Cangene Corp. won U.S. approval for its antidote for the botulism toxin considered a bioterrorism threat. The Food and Drug Administration cleared the antitoxin, the agency said today in a statement.
FDA approves first Botulism Antitoxin for use in neutralizing all seven known ... -
Cangene takeover might not be a bad thing
Winnipeg Free Press - Dec 20, 2013
Here is the New Winnipeg Free Press Homepage. Our new homepage is designed to serve you better. You'll now find this page separated into sections for Top News, Sports, Arts & Life, Opinion, Local and Business.
Cangene Granted Exclusive US Commercialization Rights for episilĀ® by Camurus AB
Canada NewsWire (press release) - Jul 9, 2012
WINNIPEG AND LUND, Sweden, July 9, 2012 /CNW/ - Cangene Corporation (Cangene) and Camurus AB announced today that they have entered into an agreement under which Cangene bioPharma Inc., a wholly-owned subsidiary of Cangene, will have ...
WinRho SDF for ITP: Cangene announces new safety information - Mar 27, 2010
Cangene Corporation, in consultation with Health Canada, is informing Canadian patients and healthcare professionals of important new safety information concerning the use of WinRho(R) SDF (Rho (D) Immune Globulin (Human)) for the treatment of ...